Just as they did with Sarepta Therapeutics, Inc.’s Exondys 51 (eteplirsen), patient groups view the company’s gene therapy candidate in Duchenne muscular dystrophy as a foundation to unlock more investment in the disease.
SRP-9001 (delandistrogene moxeparvovec), which is under priority review for accelerated approval by the US Food and Drug Administration, will benefit...








